

Senator the Hon Anne Ruston

Shadow Minister for Health and Aged Care Shadow Minister for Sport Manager of Opposition Business in the Senate Senator for South Australia

Mr Blair Comley PSM Secretary Department of Health and Aged Care *Via email: <u>blair.comley@health.gov.au</u>*

Dear Secretary Comley,

While I understand that you and your Department will attend Senate Estimates with detailed information regarding the operations of the Department of Health and Aged Care and portfolio agencies, I write to request that the Department provides the following specific information prior to your attendance before the Community Affairs Committee.

- Summary and timelines of all current reviews or similar being managed by the Department of Health (announced, commenced, awaiting response from Government).
- Urgent Care Clinics:
 - Total additional services provided at each clinic since commencement of operations in June 2023
 - A breakdown of the opening hours across each clinic.
 - A breakdown of 10 most common condition(s) being treated at Medicare Urgent Care Clinics (total numbers and percentage) since commencement of operations in June 2023.
- A breakdown of medicines that have received a positive PBAC recommendation since June 2022 but have not been listed on the PBS.
- An update on COVID-19 Vaccination rates consolidated by month since 1 July 2022 broken down by State and Territory, aged group and in residential aged care facilities as per previous request for October Estimates.
- An update on Aged Care COVID-19 mortality data, per month since 1 July 2022 as per previous request for October Estimates.
- Forecast gap of registered nurses required in residential aged care home from now until 1 October 2024 when the next care minutes requirements come into effect.
- A breakdown of current care workforce numbers across Australia, including registered nurses, enrolled nurses, general practitioners, disability care workers, and aged care workers.

- An update in the exact same format to SQ23-000561, and SQ23-001647 from 1 June 2023 to now.
- Noting that providers do provide their balance sheets to the Department of Health and Aged Care, and prove quarterly financial updates, can you provide a de-identified list of all the outstanding Covid Aged Care Support Program grants and how much is owed to each provider? Please provide this update in the same format as SQ23-000558 'Attachment A', including a total of how many grants and what value of grants have been repaid since this QoN was tabled.
- How many aged care residential facilities are currently operating with volunteer board members? Of those, what is their size, in number of beds, and where are they located across the Modified Monash Model?

Please note that this list of topics is not exhaustive, and Opposition Senators will have other questions referring to expenditure across the Department of Health and Aged Care and Sport portfolios.

Thank you in advance.


Kind Regards,

Senator Anne Ruston 6 February 2024

COVID-19 Vaccinations: 1 July 2022 to 31 January 2024

COVID-19

COVID-19 daily doses administered by age group 1 July 2022 - 31 January 2024



Administration of vaccine doses may be impacted by public holidays.

Source: Australian Immunisation Register as at 08 February 2024

Enquiry:

Urgent Care Clinics:

- Total additional services provided at each clinic since commencement of operations in June 2023
- A breakdown of the opening hours across each clinic.
- A breakdown of 10 most common condition(s) being treated at Medicare Urgent Care Clinics (total numbers and percentage) since commencement of operations in June 2023.

Response:

Opening hours and number of presentations:

Data is available below for the number of presentations for each Medicare Urgent Care Clinic (UCC) as at 5 February 2024, unless otherwise specified.

#	State	Clinic	Opening Date	Total number of presentations (as at 5 February 2024, unless otherwise specified)	Opening hours (as publicly advertised as at 9 February 2024)
1		Albury Medicare UCC	26 July 2023	1,823	8:30am-5pm Mon-Fri 10am-2pm Sat-Sun
2		Batemans Bay Medicare UCC	4 December 2023	819**	8am-6pm Mon-Sun
3		Campbelltown Medicare UCC	12 December 2023	601	8am-6pm Mon-Sun
4		Cessnock Medicare UCC	3 October 2023	2,604	8am-6pm Mon-Sun
5		Coffs Harbour Medicare UCC	20 November 2023	880	8am-6pm Mon-Sun
6		Lake Haven Medicare UCC	11 December 2023	288**	8am-7pm Mon-Fri 9am-7pm Sat-Sun
7	NSW	Lismore Medicare UCC	20 November 2023	852	8am-5pm Mon-Fri 8am-8pm Sat-Sun
8		Maroubra Medicare UCC	19 July 2023	4,719	8am-8pm Mon-Sun
9		Peninsula Medicare UCC	20 November 2023	1,873	8:30am-8pm Mon-Fri 8:30am-6:30pm Sat-Sun
10		Penrith Medicare UCC	14 August 2023	1,824	8am-8pm Mon-Sun
11		Rooty Hill Medicare UCC	7 August 2023	2,696	8am-8pm Mon-Sun
12		Tamworth Medicare UCC	30 October 2023	2,522	12pm-8pm Mon-Fri 9am-5pm Sat-Sun
13		Westmead Medicare UCC	27 July 2023	2,781	8am-8pm Mon-Sun
14		Wollongong Medicare UCC	26 July 2023	4,151	8am-8pm Mon-Sun
15	QLD	Bundaberg Medicare UCC	20 November 2023	1,138	8am-5pm Mon-Fri 8am-6pm Sat - Sun
16		Cairns South Medicare UCC	19 December 2023	985	12pm-8pm Mon-Fri

					10am-6pm Sat-Sun
17		Gold Coast Medicare UCC	13 November 2023	987	8am-10pm Mon-Sun
18		Ipswich Medicare UCC	28 August 2023	3,499	7am-10pm Mon-Sun
19		Logan (Browns Plains) Medicare UCC	14 August 2023	5,139	8am-10pm Mon-Sun
20		Murrumba Downs Medicare UCC	16 October 2023	2,176	8am-8pm Mon-Sun
21		Northside Medicare UCC	15 December 2023	903	8am-8pm Mon-Sun
22		Rockhampton Medicare UCC	6 December 2023	1,762^	8am-5pm Mon-Sun
23		South Brisbane Medicare UCC	23 October 2023	2,003	8am-8pm Mon-Sun
24		Toowoomba Medicare UCC	23 October 2023	2,835	7am – 10pm Mon-Fri 8am-10pm Sat-Sun
25		Townsville Medicare UCC	18 December 2023	1,616	11am-9pm Mon-Sun
26		Devonport Medicare UCC	11 December 2023	1,267	2pm-8pm Mon-Sun
27	TAC	Hobart (Bathurst Street) Medicare UCC	14 August 2023	3,509	4pm-10pm Mon-Sun
28	TAS	Hobart (Liverpool Street) Medicare UCC	30 October 2023	2,317	12pm-8pm Mon-Sun
29		Launceston Medicare UCC	31 July 2023	7,547	2pm-8pm Mon-Sun
30		Ballarat Medicare UCC*	17 May 2023*	8,410	10am-10pm Mon-Sun
31		Frankston Medicare UCC*	17 May 2023*	11,159	8am-12am Mon-Sun
32		Geelong Medicare UCC*	17 May 2023*	7,136	7:30am-9:30pm Mon-Sun
33		Heidelberg Medicare UCC*	17 May 2023*	9,575	10am-12am Mon-Sun
34		Inner Melbourne Medicare UCC	15 December 2023	467**	8am-10pm Mon-Sun
35	VIC	Narre Warren Medicare UCC*	17 May 2023*	5,975	8am-10pm Mon-Sun
36		Prahran Medicare UCC*	17 May 2023*	7,897	8am-10pm Mon-Sun
37		Shepparton Medicare UCC*	17 May 2023*	1,586	8am-10pm Sun-Fri 8am-4:30pm Sat
38		Sunbury Medicare UCC*	17 May 2023*	6,934	8am-10pm Mon-Sun
39		Werribee Medicare UCC*	17 May 2023*	6,239	8am-10pm Mon-Sun
40		Beeliar Medicare UCC	15 November 2023	2,941	7am-9pm Mon-Fri 8am-8pm Sat-Sun
41	WA	Broome Medicare UCC	28 December 2023	273	8am-4pm Mon-Sun
42		Clarkson Medicare UCC	21 August 2023	6,645	8am-6pm Mon-Sun
43		Greater Bunbury Medicare UCC	20 November 2023	3,240	7am-8pm Mon-Sun

44		Midland Medicare UCC	11 December 2023	371**	9am-6pm Mon-Fri 9am-5pm Sat-Sun
45		Perth City Medicare UCC	30 June 2023	3,720	8am-8pm Mon-Sun
46		Rockingham Medicare UCC	30 June 2023	5,780	8am-8pm Mon-Sun
47	NT	Mparntwe (Alice Springs) Medicare UCC	4 December 2023	641^	12pm-8pm Mon-Fri 12pm-4pm Sat-Sun
48	NT	Palmerston Medicare UCC	1 October 2023	2,888	12:30pm-8:30pm Mon-Fri 10am-6pm Sat-Sun
49		Elizabeth Medicare UCC	23 October 2023	1,997	8am-8pm Mon-Sun
50		Marion Medicare UCC	6 November 2023	1,970	8am-8pm Mon-Sun
51	SA	Morphett Vale Medicare UCC	28 December 2023	1,724	8am-7pm Mon-Fri 8am-3pm Sat-Sun
52		Mount Gambier Medicare UCC	20 November 2023	1,754	9am-8pm Mon-Fri 10am-6pm Sat 9am-10pm Sun
53		Western Medicare UCC	4 December 2023	1,536	10am-8pm Mon-Sun
54		Weston Creek Walk-in Centre & South Canberra Medicare UCC	18 October 2023	N/A	7:30am-10pm Mon-Sun
55		Belconnen Walk-in Centre & Medicare UCC	18 October 2023	N/A	7:30am-10pm Mon-Sun
56	ACT	Inner North (Dickson) Walk-in Centre & Medicare UCC	18 October 2023	N/A	7:30am-10pm Mon-Sun
57		Gungahlin Walk-in Centre & Medicare UCC	18 October 2023	N/A	7:30am-10pm Mon-Sun
58		Tuggeranong Walk-in Centre & Medicare UCC	18 October 2023	N/A	7:30am-10pm Mon-Sun

Please note, data for clinics in NSW, QLD, SA, WA, TAS, and the NT is from the respective opening date to the end of day 5 February 2024. Data for the VIC clinics (excluding Inner Melbourne) is presented from 30 June 2023 to end of day 14 January 2024. Data for the Inner Melbourne clinic is from its opening date to end of day 5 February 2024.

^Total visit numbers have been provided manually for Rockhampton and Alice Spring Medicare UCCs as work with the clinic continues to support the data collection process.

No data is available for ACT Medicare UCCs.

Visit numbers are based on the data entered in by Medicare UCCs, and some data may be missing due to data entry issues. If a patient does not provide consent for their information to be shared, it is not included in the above numbers.

*The Victorian clinics were operational prior to this date. However, on 17 May 2023 it was announced the Commonwealth would take over funding for the nine sites. Data for Victorian clinics is currently collected through a different process to the standard data collection, and is from 30 June 2023 to 14 January 2024.

**The numbers received by the Department are dependent on the data collection processes at each of the Medicare UCCs. Some clinics have required additional support in implementing the data collection systems. The numbers for these Medicare UCCs are underrepresented. The Department is working closely with the clinics and other stakeholders to support data collection processes.

Reasons for presentation:

Of the patients asked (approximately 22,000) over the month of January 2024:

- Approximately 6,900 or 31 per cent presented at a Medicare UCC for an acute injury;
- Approximately 12,600 or 57 per cent presented at a Medicare UCC for an acute illness;
- Approximately 980 or 4 per cent presented at a Medicare UCC for an acute exacerbation of a known chronic condition;
- Approximately 360 or 2 per cent presented at a Medicare UCC for a follow up; and
- Approximately 1,200 or 5 per cent presented at a Medicare UCC for another reason.

	Primary Course	s defined as any o	dose of third or lo	ower in sequence	7 July 2022 - Up	dated Winter Dos	e Recommendat	ions	7 February 2023	- ATAGI advice o	n COVID-19 vacc	ine doses		1 September 202	23 - Additional Do	ose			
		individuals, or two				o 64 years are no				nonths since a CO			OVID-19			s aged ≥ 75 years	should receive a	n additional	
						ose of a COVID-1			infection, an add							8 ,			
	This number is ar	n estimate as a nu	umber of individu	als in special	vaccine.	050 01 0 00 010 1.	- -		· · ·	d for people aged	d 75 years or olde	ar.		2023 COVID-19 V	accine dose if 6 n	nonths have passe	d since their last	dose or confirme	d infection and
				-	vaccine.						-								
		ill have required a	a difference numi	ber of doses to						idered for people					• •	18-64 years with	severe immunoc	compromise shou	lid consider an
Residential Aged Care	complete a prima	-							1.	e immunocompro	omise following di	iscussion with the	ir healthcare	additional 2023					
Home		nunocompromise							provider.					Aged care reside	nts who have not	yet received any	booster dose this	s year are advised	l to do so.
	doses at all ages,	or those who rec	eived a Johnson	and Johnson					All COVID-19 vac	cines are anticipa	ated to provide be	enefit to eligible p	eople. However,						
	vaccination overs	seas will have only	y required one do	ose.					the monovalent	Omicron XBB.1.5	vaccines are pref	erred over other	vaccines for						
									eligible people.										
RACH	Jul-22	Aug-22	Sep-22	Oct-22	Nov-22	Dec-22	Jan-23	Feb-23	Mar-23	Apr-23	May-23	Jun-23	Jul-23	Aug-23	Sep-23	Oct-23	Nov-23	Dec-23	Jan-24
Primary Course	178,335 (95%)	179,605 (95%)	180,705 (95%)	181,235 (96%)	181,705 (96%)	181,190 (96%)	181,905 (96%)	183,250 (96%)	184,200 (96%)	183,645 (96%)	184,405 (96%)	185,230 (96%)	185,420 (96%)	186,480 (96%)	186,760 (96%)	186,935 (96%)	184,190 (96%)	181,550 (96%)	179,615 (96%
Dose 3+	168,410 (90%)	170,645 (91%)	172,260 (91%)	173,030 (91%)	173,845 (91%)	173,510 (92%)	174,140 (92%)	175,345 (92%)	176,350 (92%)	176,090 (92%)	177,330 (92%)	178,400 (92%)	178,720 (92%)	179,835 (92%)	180,010 (92%)	180,205 (92%)	177,685 (92%)	175,315 (93%)	173,575 (939
Dose 4+	114,020 (61%)	125,765 (67%)	132,475 (70%)	136,000 (72%)	139,650 (73%)	141,275 (75%)	142,005 (75%)	143,215 (75%)	145,410 (76%)	147,260 (77%)	152,105 (79%)	155,420 (80%)	157,135 (81%)	158,645 (81%)	159,005 (82%)	159,435 (82%)	157,960 (82%)	157,005 (83%)	155,995 (839
Dose 5+	1,435 (1%)	1,760 (1%)	1,975 (1%)	2,145 (1%)	2,425 (1%)	2,625 (1%)	2,785 (1%)	3,835 (2%)	16,130 (8%)	34,050 (18%)	61,355 (32%)	77,850 (40%)	88,270 (46%)	93,930 (48%)	96,625 (50%)	99,210 (51%)	102,370 (53%)	107,465 (57%)	110,355 (59%
Dose 6+	50 (0%)	55 (0%)	65 (0%)	70 (0%)	75 (0%)	85 (0%)	85 (0%)	120 (0%)	425 (0%)	775 (0%)	1.380 (1%)	1,790 (1%)	2,160 (1%)	2.390 (1%)	3,120 (2%)	5,865 (3%)	13,305 (7%)	25.305 (13%)	32,995 (18%
Primary Course	2,375 (97%)	2,395 (97%)	2,430 (97%)	2,435 (97%)	2,445 (97%)	2,425 (97%)	2,440 (97%)	2,435 (97%)	2,445 (97%)	2,430 (97%)	2,435 (97%)	2,455 (97%)	2,465 (97%)	2,490 (97%)	2,490 (97%)	2,480 (97%)	2,430 (97%)	2,410 (97%)	2,395 (97%)
Dose 3+	2,300 (94%)	2,330 (94%)	2,365 (94%)	2,370 (94%)	2,380 (94%)	2,360 (94%)	2,375 (94%)	2,370 (94%)	2,380 (94%)	2,375 (95%)	2,380 (95%)	2,400 (95%)	2,410 (95%)	2,430 (95%)	2,425 (95%)	2,420 (95%)	2,375 (95%)	2,355 (95%)	2,345 (95%)
Dose 4+	1,645 (67%)	1,815 (73%)	1,950 (78%)	1,995 (79%)	2,040 (81%)	2,035 (81%)	2,045 (81%)	2,050 (81%)	2,095 (83%)	2,115 (84%)	2,155 (86%)	2,205 (87%)	2,240 (88%)	2,270 (88%)	2,275 (89%)	2,260 (89%)	2,220 (89%)	2,210 (89%)	2,205 (90%)
Dose 5+	20 (1%)	25 (1%)	35 (1%)	35 (1%)	40 (2%)	35 (1%)	35 (1%)	50 (2%)	465 (18%)	815 (33%)	1,080 (43%)	1,285 (51%)	1,415 (56%)	1,510 (59%)	1,540 (60%)	1,590 (62%)	1,645 (66%)	1,730 (70%)	1,770 (72%)
Dose 5+ Dose 6+	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	<10 (0%)	10 (0%)	20 (1%)	30 (1%)	35 (1%)	45 (2%)	60 (2%)	275 (11%)	440 (18%)	640 (26%)	765 (31%)
	58,290 (96%)	58.580 (96%)	58,975 (96%)	59.040 (96%)	59,180 (96%)	58.880 (96%)	59,095 (96%)	59.575 (96%)	<10 (0%) 59,915 (96%)	59.695 (96%)	59,935 (96%)	60.125 (96%)	60,255 (96%)	45 (2%) 60.645 (96%)	60,785 (96%)	60,790 (96%)	440 (18%) 59,885 (96%)	58.990 (96%)	58,345 (96%
Primary Course	, , ,		, , ,		, , ,		, , ,		, , ,		, , ,	, . (,	, , ,		, , ,	, , ,	, , ,		
Dose 3+	54,945 (90%)	55,530 (91%)	56,050 (91%)	56,190 (91%)	56,430 (92%)	56,180 (92%)	56,340 (92%)	56,780 (92%)	57,155 (92%)	57,040 (92%)	57,430 (92%)	57,720 (92%)	57,895 (92%)	58,295 (92%)	58,415 (92%)	58,460 (93%)	57,630 (93%)	56,820 (93%)	56,245 (93%
Dose 4+	36,865 (61%)	40,575 (66%)	42,420 (69%)	43,295 (70%)	44,340 (72%)	44,965 (73%)	45,195 (73%)	45,745 (74%)	46,540 (75%)	47,185 (76%)	48,920 (78%)	49,935 (80%)	50,570 (81%)	51,125 (81%)	51,310 (81%)	51,405 (81%)	50,935 (82%)	50,670 (83%)	50,385 (83%
Dose 5+	545 (1%)	655 (1%)	725 (1%)	780 (1%)	855 (1%)	955 (2%)	1,025 (2%)	1,360 (2%)	5,155 (8%)	10,835 (17%)	19,600 (31%)	24,910 (40%)	27,955 (45%)	29,750 (47%)	30,560 (48%)	31,295 (50%)	32,475 (52%)	34,260 (56%)	35,305 (58%
Dose 6+	10 (0%)	10 (0%)	15 (0%)	15 (0%)	20 (0%)	20 (0%)	20 (0%)	40 (0%)	195 (0%)	305 (0%)	500 (1%)	650 (1%)	780 (1%)	880 (1%)	1,120 (2%)	1,870 (3%)	4,355 (7%)	8,530 (14%)	10,870 (18%)
Primary Course	520 (93%)	525 (93%)	535 (94%)	540 (94%)	535 (94%)	545 (94%)	540 (93%)	535 (94%)	535 (94%)	530 (93%)	525 (93%)	540 (94%)	540 (94%)	535 (94%)	540 (94%)	540 (94%)	540 (95%)	520 (94%)	525 (95%)
Dose 3+	490 (88%)	500 (89%)	505 (89%)	510 (89%)	510 (89%)	515 (89%)	515 (89%)	505 (89%)	505 (89%)	500 (88%)	495 (88%)	505 (88%)	510 (89%)	500 (88%)	505 (88%)	505 (88%)	505 (89%)	490 (89%)	490 (88%)
Dose 4+	305 (55%)	340 (60%)	365 (64%)	375 (65%)	390 (68%)	390 (67%)	395 (68%)	390 (68%)	395 (70%)	390 (69%)	395 (70%)	410 (72%)	415 (72%)	415 (73%)	420 (73%)	415 (72%)	425 (75%)	415 (75%)	415 (75%)
Dose 5+	15 (3%)	15 (3%)	15 (3%)	20 (3%)	20 (4%)	25 (4%)	25 (4%)	25 (4%)	35 (6%)	40 (7%)	120 (21%)	145 (25%)	170 (30%)	180 (32%)	180 (31%)	185 (32%)	235 (41%)	235 (43%)	240 (43%)
Dose 6+	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	<10 (1%)	10 (2%)	15 (3%)	20 (3%)	15 (3%)	20 (3%)	20 (3%)	35 (6%)	50 (9%)	55 (10%)
Primary Course	35,215 (94%)	35,505 (94%)	35,785 (94%)	35,905 (94%)	36,035 (94%)	36,035 (94%)	36,160 (94%)	36,485 (94%)	36,630 (94%)	36,480 (94%)	36,565 (94%)	36,745 (94%)	36,650 (94%)	36,885 (94%)	36,940 (94%)	37,010 (94%)	36,510 (94%)	35,955 (94%)	35,565 (95%
Dose 3+	33,140 (88%)	33,575 (89%)	33,920 (89%)	34,125 (90%)	34,330 (90%)	34,360 (90%)	34,490 (90%)	34,780 (90%)	34,915 (90%)	34,850 (90%)	35,055 (91%)	35,265 (91%)	35,185 (91%)	35,445 (91%)	35,475 (91%)	35,530 (91%)	35,095 (91%)	34,605 (91%)	34,255 (91%
Dose 4+	22,320 (60%)	24,360 (65%)	25,385 (67%)	26,270 (69%)	27,145 (71%)	27,520 (72%)	27,710 (72%)	27,990 (72%)	28,435 (73%)	28,845 (75%)	29,770 (77%)	30,485 (78%)	30,675 (79%)	31,025 (79%)	31,100 (79%)	31,190 (80%)	30,975 (80%)	30,740 (81%)	30,565 (81%
Dose 5+	250 (1%)	315 (1%)	335 (1%)	350 (1%)	425 (1%)	450 (1%)	465 (1%)	600 (2%)	2,875 (7%)	6,590 (17%)	11,775 (30%)	14,730 (38%)	16,420 (42%)	17,640 (45%)	18,290 (47%)	18,690 (48%)	19,370 (50%)	20,230 (53%)	21,025 (56%
Dose 6+	<10 (0%)	<10 (0%)	<10 (0%)	<10 (0%)	10 (0%)	10 (0%)	10 (0%)	15 (0%)	60 (0%)	130 (0%)	265 (1%)	330 (1%)	385 (1%)	415 (1%)	490 (1%)	690 (2%)	2,095 (5%)	4,190 (11%)	6,245 (17%)
Primary Course	15,460 (94%)	15,550 (94%)	15,650 (95%)	15,675 (95%)	15,785 (95%)	15,660 (95%)	15,775 (95%)	15,885 (95%)	15,920 (95%)	15,855 (95%)	15,950 (95%)	16,005 (95%)	16,000 (95%)	16,115 (95%)	16,085 (95%)	16,145 (95%)	15,930 (95%)	15,675 (95%)	15,505 (95%
Dose 3+	14,500 (88%)	14.690 (89%)	14.885 (90%)	14,925 (90%)	15.070 (90%)	14.970 (91%)	15.080 (91%)	15,195 (91%)	15,245 (91%)	15,195 (91%)	15,365 (92%)	15,420 (92%)	15,445 (92%)	15,570 (92%)	15,545 (92%)	15.600 (92%)	15,395 (92%)	15.180 (92%)	15,020 (92%
Dose 3+ Dose 4+	9,465 (58%)	14,090 (89%)	11.475 (69%)	11,650 (70%)	12.040 (72%)	12,075 (73%)	12.215 (73%)	12,345 (74%)	12,515 (75%)	12,715 (76%)	13,160 (79%)	13,415 (80%)	13,443 (32%)	13,780 (82%)	13,800 (82%)	13,885 (82%)	13,785 (83%)	13,725 (84%)	13,650 (84%
Dose 4+ Dose 5+	, , ,	-, - ()	, - ()	, , ,	1	, , ,	,	, , ,	1,220 (7%)	2.735 (16%)	-, ()	, , ,	7,390 (81%)	-, - ()	8,305 (49%)	-,	8,795 (53%)	, , ,	-,
	100 (1%)	135 (1%)	160 (1%)	170 (1%)	230 (1%)	240 (1%)	255 (2%)	290 (2%)	, , ,	, ,	4,955 (30%)	6,260 (37%)	, , ,	8,065 (48%)	, , ,	8,525 (50%)	, , ,	9,465 (58%)	9,685 (60%)
Dose 6+	20 (0%)	20 (0%)	25 (0%)	25 (0%)	25 (0%)	25 (0%)	25 (0%)	25 (0%)	45 (0%)	80 (0%)	120 (1%)	145 (1%)	170 (1%)	195 (1%)	255 (2%)	365 (2%)	1,030 (6%)	2,165 (13%)	2,890 (18%)
Primary Course	4,285 (95%)	4,310 (95%)	4,355 (95%)	4,355 (95%)	4,355 (95%)	4,350 (95%)	4,375 (95%)	4,390 (95%)	4,400 (95%)	4,365 (95%)	4,390 (95%)	4,390 (95%)	4,385 (96%)	4,400 (95%)	4,380 (95%)	4,375 (95%)	4,285 (95%)	4,205 (95%)	4,160 (95%)
Dose 3+	4,045 (89%)	4,085 (90%)	4,165 (91%)	4,170 (91%)	4,180 (91%)	4,190 (92%)	4,215 (92%)	4,225 (92%)	4,245 (92%)	4,230 (92%)	4,260 (92%)	4,280 (93%)	4,265 (93%)	4,280 (93%)	4,255 (93%)	4,250 (93%)	4,165 (93%)	4,095 (93%)	4,055 (93%)
Dose 4+	2,625 (58%)	2,950 (65%)	3,250 (71%)	3,320 (72%)	3,450 (75%)	3,495 (76%)	3,495 (76%)	3,530 (77%)	3,575 (77%)	3,635 (79%)	3,755 (81%)	3,825 (83%)	3,845 (84%)	3,875 (84%)	3,855 (84%)	3,860 (84%)	3,820 (85%)	3,780 (86%)	3,775 (86%)
Dose 5+	45 (1%)	55 (1%)	65 (1%)	70 (2%)	75 (2%)	80 (2%)	80 (2%)	125 (3%)	530 (11%)	1,145 (25%)	1,755 (38%)	2,235 (49%)	2,485 (54%)	2,620 (57%)	2,630 (57%)	2,725 (59%)	2,800 (62%)	2,905 (66%)	2,980 (68%)
Dose 6+	0 (0%)	0 (0%)	<10 (0%)	<10 (0%)	<10 (0%)	<10 (0%)	<10 (0%)	<10 (0%)	15 (0%)	25 (1%)	50 (1%)	65 (1%)	85 (2%)	95 (2%)	160 (3%)	265 (6%)	615 (14%)	985 (22%)	1,210 (28%)
Primary Course	46,080 (96%)	46,385 (96%)	46,560 (96%)	46,760 (96%)	46,830 (96%)	46,745 (96%)	46,870 (96%)	47,180 (96%)	47,440 (96%)	47,365 (96%)	47,620 (96%)	47,880 (96%)	47,945 (96%)	48,175 (96%)	48,260 (96%)	48,235 (96%)	47,510 (96%)	46,980 (96%)	46,485 (96%
Dose 3+	43,940 (91%)	44,495 (92%)	44,765 (92%)	44,995 (93%)	45,115 (93%)	45,055 (93%)	45,175 (93%)	45,415 (93%)	45,685 (93%)	45,660 (93%)	46,025 (93%)	46,340 (93%)	46,420 (93%)	46,650 (93%)	46,680 (93%)	46,660 (93%)	45,965 (93%)	45,480 (93%)	45,030 (93%
Dose 4+	31,590 (66%)	34,355 (71%)	36,245 (75%)	37,040 (76%)	37,800 (78%)	38,060 (78%)	38,155 (78%)	38,285 (78%)	38,750 (79%)	39,240 (80%)	40,370 (82%)	41,160 (83%)	41,530 (83%)	41,745 (83%)	41,765 (83%)	41,880 (84%)	41,425 (84%)	41,245 (85%)	40,885 (85%
Dose 5+	365 (1%)	440 (1%)	505 (1%)	555 (1%)	595 (1%)	650 (1%)	695 (1%)	1,160 (2%)	4,890 (10%)	9,980 (20%)	17,750 (36%)	22,415 (45%)	25,370 (51%)	26,415 (53%)	27,065 (54%)	27,975 (56%)	28,565 (58%)	29,790 (61%)	30,230 (63%
Dose 6+	10 (0%)	15 (0%)	15 (0%)	15 (0%)	15 (0%)	15 (0%)	15 (0%)	25 (0%)	85 (0%)	185 (0%)	330 (1%)	450 (1%)	540 (1%)	580 (1%)	765 (2%)	2,070 (4%)	4,035 (8%)	7,410 (15%)	9,135 (19%
Primary Course	16,020 (95%)	16.255 (96%)	16.315 (96%)	16.415 (96%)	16.420 (96%)	16.435 (96%)	16.520 (96%)	16.650 (96%)	16,785 (96%)	16,790 (96%)	16.835 (96%)	16.935 (96%)	17.015 (96%)	17.070 (96%)	17,110 (96%)	17.180 (96%)	16.925 (96%)	16,645 (96%)	16,460 (96%
Dose 3+	14,965 (89%)	15,355 (90%)	15,510 (91%)	15,650 (91%)	15,720 (92%)	15,765 (92%)	15.840 (92%)	15,955 (92%)	16,100 (92%)	16.110 (92%)	16,180 (92%)	16,330 (93%)	16.440 (93%)	16,510 (93%)	16,550 (93%)	16,620 (93%)	16.385 (93%)	16,135 (93%)	15,970 (93%
Dose 3+	9,150 (54%)	10,580 (62%)	11,315 (66%)	11,975 (70%)	12,370 (72%)	12,650 (74%)	12,700 (74%)	12,795 (74%)	13,010 (75%)	13,035 (75%)	13,475 (77%)	13,870 (79%)	16,440 (93%)	14,280 (81%)	14,340 (81%)	14,395 (81%)	14,240 (81%)	14,085 (82%)	13,980 (82%
	9,150 (54%) 100 (1%)	, , ,	, , ,	, , ,	12,370 (72%) 180 (1%)	, , ,	, , ,	, , ,	940 (5%)	, , ,	, , ,	, , ,	6.985 (40%)	, , ,	, , ,	8.135 (46%)	8,400 (48%)	, , ,	, ,
Dose 5+		125 (1%)	135 (1%)	175 (1%)		190 (1%)	195 (1%)	215 (1%)	()	1,870 (11%)	4,270 (24%)	5,805 (33%)	-,	7,675 (43%)	7,970 (45%)	-, (,	-, - (-)	8,770 (51%)	9,025 (53%)
Dose 6+	<10 (0%)	<10 (0%)	<10 (0%)	<10 (0%)	<10 (0%)	<10 (0%)	<10 (0%)	10 (0%)	20 (0%)	35 (0%)	75 (0%)	100 (1%)	140 (1%)	155 (1%)	245 (1%)	295 (2%)	680 (4%)	1,315 (8%)	1,795 (11%)

Specifics

Specifics low Population Suppression: Cells have been suppressed with < 10 when the total population in the cell has a value greater than 0 or less than 10.

Cumulative population: count values included represent total cumulative number of individuals vaccinated up to the end of the month as stated. Back dated data: General population records are reported as of encounter date not date of first reporting. This will vary significantly from other published data due to back dated records being recorded at a later date.

Individual dose status includes all individuals in dose number higher categories. For example, Dose 3+ includes all individuals who have had dose 4 or higher. As a result, state totals by dose number are not additive.

Doses administered includes all doses administered to individuals regardless of dose sequence number. RACH dynamic population: The RACH population size is dynamic over time, including for those of a particular vaccination status, so counts may occasionally decrease over time.

Caveats

Encounter month is based on the date of physical administration as reported in AIR, not the date of first reporting which may differ from other published figures.

End dated Records: Due to the time series nature of this extract, end dated individuals are included even if they have subsequently died or permanently emigrated from Australia. These individuals are usually removed from point-in-time person level reporting. RACH suppression: Suppression has been applied to ensure privacy. Specifically, counts between 1 and 9 have been replaced with "< 10 when the total population in the cell has a value greater than 0 or less than 10.

RACH dynamic Population: The RACH population size is dynamic over time, including for those of a particular vaccination status, so counts may occasionally decrease over time.

RACH total counts: The total counts are the totals among those that can be linked to their Medicare enrolment details, which is a subset of total residents. An adjusted estimation of all (not just linked) can be provided on request, by vaccination status. RACH data revisions: Due to revisions in previous aged care and AIR records, for example lagging records, the numbers may differ to analysis carried out in the past.

RACH differences from publicly reported figures: The aged care vaccination rates differ from public reporting because these rates are calculated differently. For example, the public reporting shows the number of aged care residents who have received a booster dose (i.e., dose 3+) since 1 January 2023. However, the vaccination rates presented here has no date range limit. RACH method overview: To determine vaccine coverage rates in residential aged care homes, data is merged from three sources (1) Residential Aged Care recipient data from the Aged Care Payment System (ACPS). This data contains information about where recipients live. (2) Australian Immunisation Register vaccination records (3) RACH recipient ID to Medicare PIN linkage map (concordance file) produced and updated by AIHW. This concordance file is used to merge individual RACH recipients to their immunisation records.

<u>Health Resourcing Group</u> - Technology Assessment and Access Division February 2024 Senate Estimates - request from Senator the Hon Anne Ruston

Request:

The Medicine Status Website (MSW) provides searchable information about the status of medicines as they progress through the PBS listing process. The MSW contains all Pharmaceutical Benefits Advisory Committee (PBAC) recommendations from July 2019 onwards. The website is updated monthly and can be accessed at: www.pbs.gov.au/medicinestatus/home.html .

While this information is publicly available, the Department has provided a list of medicines that received a positive PBAC recommendation since June 2022 which have not been listed on the PBS, and information that can be provided publicly about where they are in the listing process. This reflects information available at **12 February 2024**.

PBAC Meeting	Government processes commenced	Listing proposal under consideration	No Listing proposal received	No listing proposal consistent with PBAC	Sponsor resubmit to PBAC	TOTAL
Corresponding Medicine Status Website step	Step 7	Step 5 – Step 6	Step 4 – Step 4a	Step 5a - "not accepted"	N/A	N/A
DECEMBER 2023	1		2			3
NOVEMBER 2023	7	12	5	1		25
SEPTEMBER 2023	1			1		2
JULY 2023	5			1	1	7
MAY 2023	1					1
MARCH 2023	3		1		1	5
DECEMBER 2022					1	1
NOVEMBER 2022			3			3
JULY 2022			2			2
TOTAL	18	12	13	3	3	49

Table 1 - Summary of the status of PBAC recommendations since June 2022

Table 2 – PBAC recommendations since June 2022 by medicine

PBAC MEETING DECEMBER 2023					
MEDICINE	INDICATION	STATUS			
MELATONIN Slenyto®	Insomnia	No listing proposal received			
PATISIRAN Onpattro®	Hereditary transthyretin- mediated amyloidosis	No listing proposal received			
UPADACITINIB Rinvoq®	Rheumatoid arthritis	Government processes commenced			
PBAC MEETING NOVEMBER 2023					
MEDICINE	INDICATION	STATUS			
ABEMACICLIB Verzenio®	Early breast cancer	Government processes commenced			

ADALIMUMAB Hadlima®	Crohn disease; ulcerative colitis; severe active juvenile idiopathic arthritis; fistulising Crohn disease; rheumatoid arthritis; psoriatic arthritis; ankylosing spondylitis; chronic plaque psoriasis; hidradenitis suppurativa	No listing proposal received
APREMILAST Otezla®	Chronic plaque psoriasis	Listing proposal under consideration
BUDESONIDE + FORMOTEROL Bufomix Easyhaler®	Asthma; Chronic obstructive pulmonary disease	Government processes commenced
CEMIPLIMAB Libtayo®	Non-small cell lung cancer	Government processes commenced
CHLORMETHINE HYDROCHLORIDE Ledaga®	Mycosis fungoides-type cutaneous T-cell lymphoma	Listing proposal under consideration
DAUNORUBICIN WITH CYTARABINE Vyxeos®	Acute myeloid leukaemia	Listing proposal under consideration
DIFELIKEFALIN Korsuva®	Chronic kidney disease associated pruritus	Listing proposal under consideration
DOSTARLIMAB Jemperli®	Endometrial cancer	Listing proposal under consideration
ELTROMBOPAG Revolade®	Aplastic anaemia	No listing proposal received
EMPAGLIFLOZIN Jardiance®	Chronic kidney disease	Listing proposal under consideration
FLUTICASONE PROPIONATE + SALMETEROL Salflumix Easyhaler [®]	Asthma; chronic obstructive pulmonary disease	Government processes commenced
IVACAFTOR Kalydeco®	Cystic fibrosis (from 4 months)	No listing proposal consistent with PBAC advice received
LENACAPAVIR Sunlenca®	Human immunodeficiency virus (HIV)	No listing proposal received
LENALIDOMIDE Lenalide®	Multiple myeloma; myelodysplastic syndromes; mantle cell lymphoma	Listing proposal under consideration
MAVACAMTEN Camzyos®	Hypertrophic cardiomyopathy	Government processes commenced
MEDROXYPROGESTERONE ACETATE Depo-provera®	Contraception; endometriosis	Government processes commenced
MIDAZOLAM Zyamis®	Generalised convulsive status epilepticus	Listing proposal under consideration
OLAPARIB Lynparza®	Human epidermal growth factor receptor 2 (HER2)-negative early breast cancer	Listing proposal under consideration
OSIMERTINIB Tagrisso [®]	Non-small cell lung cancer	Listing proposal under consideration

MEDICINE	INDICATION	STATUS
PBAC MEETING MARCH 2023		
INCLISIRAN Leqvio®	Hypercholesterolaemia	Government processes commenced
MEDICINE	INDICATION	STATUS
PBAC MEETING MAY 2023		
Vyndamax®	cardiomyopathy	commenced
SOMAPACITAN Sogroya® TAFAMIDIS	Paediatric growth hormone deficiency Transthyretin amyloid	consistent with PBAC advice received Government processes
NUSINERSEN Spinraza®	Pre-symptomatic spinal muscular atrophy	Government processes commenced No listing proposal
NIVOLUMAB Opdivo®	Non-small cell lung cancer (neoadjuvant)	No listing proposal received The sponsor has made a further submission to the PBAC at its March 2024 meeting
NIRAPARIB Zejula®	Epithelial ovarian, fallopian tube, or primary peritoneal cancer	Government processes commenced
DAPAGLIFLOZIN Forxiga®	Chronic heart failure	Government processes commenced
ABIRATERONE AND METHYLPREDNISOLONE Yonsa® Mpred	Metastatic hormone sensitive prostate cancer	Government processes commenced
MEDICINE	INDICATION	STATUS
PBAC MEETING JULY 2023		
CHORIOGONADOTROPIN ALFA Ovidrel®	Infertility indications other than that of Assisted Reproductive Technology (ART)	Government processes commenced
CABOTEGRAVIR Apretude [®]	Pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) infection	No listing proposal consistent with PBAC advice received
MEDICINE	INDICATION	STATUS
Terrosa [®] PBAC MEETING SEPTEMBER 2023	Osteoporosis	commenced
Teriparatide Lupin® TERIPARATIDE	Osteoporosis	consideration Government processes
SECUKINUMAB Cosentyx® TERIPARATIDE	Hidradenitis suppurativa	No listing proposal received Listing proposal under
RISANKIZUMAB Skyrizi®	Chronic plaque psoriasis	Listing proposal under consideration
Keytruda®	Squamous cell carcinoma	No listing proposal received

ALIROCUMAB Praluent®	Hypercholesterolaemia (new forms)	No listing proposal received
AMINO ACID FORMULA WITH VITAMINS AND MINERALS WITHOUT VALINE, LEUCINE AND ISOLEUCINE AND SUPPLEMENTED WITH ARACHIDONIC ACID AND DOCOSAHEXAENOIC ACID MSUD explore5 [™]	Maple syrup urine disease	Government processes commenced
AMINO ACID FORMULA WITH VITAMINS AND MINERALS, WITHOUT METHIONINE AND SUPPLEMENTED WITH ARACHIDONIC ACID AND DOCOSAHEXAENOIC ACID HCU explore5™	Pyridoxine non-responsive homocystinuria	Government processes commenced
AMINO ACID FORMULA WITH VITAMINS AND MINERALS, WITHOUT PHENYLALANINE AND TYROSINE AND SUPPLEMENTED WITH ARACHIDONIC ACID AND DOCOSAHEXAENOIC ACID TYR explore5™	Tyrosinaemia	Government processes commenced
ROMOSOZUMAB Evenity®	Osteoporosis	No listing proposal consistent with PBAC advice received The sponsor has made a further submission to the PBAC for consideration at its March 2024 meeting
PBAC MEETING DECEMBER 2022		
MEDICINE	INDICATION	STATUS
MIGALASTAT Galafold®	Fabry disease	No listing proposal received The sponsor has made a further submission to the PBAC for consideration at its March 2024 meeting
PBAC MEETING NOVEMBER 2022	J	
MEDICINE	INDICATION	STATUS
DUPILUMABChronic severe atopic dermatDupixent®Uncontrolled severe asthma (new form)		No listing proposal received
INFLIXIMAB Remsima [®] SC	Rheumatoid arthritis	No listing proposal received

RISANKIZUMAB Skyrizi®	Crohn's disease	No listing proposal received
PBAC MEETING JULY 2022		
MEDICINE	INDICATION	STATUS
HUMAN MENOPAUSAL GONADOTROPHIN Menopur [®] 600 Menopur [®] 1200	Assisted Reproductive Technology	No listing proposal received
USTEKINUMAB Stelara®	Severe Crohn disease, Severe chronic plaque psoriasis (new form)	No listing proposal received

<u>Table 3 – Medicine sponsor has advised it will not be progressing the recommendation and</u> <u>therefore it is not possible for the Government to list on the PBS</u>

PBAC MEETING JULY 2023		
MEDICINE	INDICATION	STATUS
MIRIKIZUMAB Omvoh®	Moderate to severe ulcerative colitis	The sponsor has advised it is not proceeding to PBS listing at this time
MOBOCERTINIB Exkivity®	Locally advanced or metastatic non-small cell lung cancer	The sponsor has advised it is not proceeding to PBS listing at this time
PBAC MEETING MAY 2023		
MEDICINE	INDICATION	STATUS
CARMELLOSE WITH GLYCERIN AND HYALURONIC ACID Optive fusion®	Severe dry eye syndrome	The sponsor has advised it is not proceeding to PBS listing at this time
HYALURONIC ACID WITH POLYETHYLENE GLYCOL 400 WITH PROPYLENE GLYCOL WITH HYDROXYPROPYL GUAR Systane® Hydration	Severe dry eye syndrome	The sponsor has advised it is not proceeding to PBS listing at this time
PBAC MEETING NOVEMBER 2022		
MEDICINE	INDICATION	STATUS
ETANERCEPT Nepexto®	Rheumatoid arthritis; juvenile idiopathic arthritis; psoriatic arthritis; plaque psoriasis; ankylosing spondylitis	The sponsor has advised it is not proceeding to PBS listing at this time
PBAC MEETING JULY 2022		
PROGESTERONE Cyclogest®	Infertility	The sponsor has advised it is not proceeding to PBS listing at this time

At 1 February 2024, there have been 3,409 COVID-19 related deaths in Residential Aged Care Homes since 1 July 2022.

Month	COVID-19 Deaths	All-Cause Deaths	Proportion
July 2022	618	6,156	10.0%
August 2022	544	5,701	9.5%
September 2022	149	4,898	3.0%
October 2022	114	4,731	2.4%
November 2022	159	4,690	3.4%
December 2022	322	5,131	6.3%
January 2023	291	4,507	6.5%
February 2023	60	4,105	1.5%
March 2023	76	4,703	1.6%
April 2023	149	4,736	3.1%
May 2023	216	5,363	4.0%
June 2023	174	5,066	3.4%
July 2023	100	5,249	1.9%
August 2023	26	5,040	0.5%
September 2023	27	4,727	0.6%
October 2023	57	4,836	1.2%
November 2023	123	4,785	2.6%
December 2023	88	4,698	1.9%
January 2024	116	4,534	2.6%
Total	3,409	93,656	N/A

Figure 1. COVID-19 related deaths in aged care since 1 July 2022

The COVID-19 data is self-reported by aged care providers via the My Aged Care Portal. Providers report all COVID-19 outbreaks, cases and deaths that occur within their residential facility through this mechanism.

The all-cause death figures are provided from the Aged Care Data Warehouse and are for residential age care residents only (*note this may be subject to change*).

For the purpose of this dataset, a COVID-19 positive death is defined as: when a resident passes away from COVID-19 or with COVID-19 when a clear alternative cause of death has not been determined.

Response to Correspondence from Senator Ruston to Secretary Comley dated 6 February 2024 regarding Senate Estimates

<u>Question</u>: The forecast gap of registered nurses required in residential aged care homes from now until 1 October 2024 when the next care minutes requirements come into effect.

The Department's estimated workforce gap is:

5,918 RNs in 2024-25.

The Department does not model specifically on a quarterly or monthly basis, so we cannot give estimates precisely to 1 October 2024. Estimates are done by financial year and are updated for the latest available data as it arises. These forecasts are based on data from the fourth instalment of the Aged Care Quarterly Financial Report (QFR) data (2022-23 Q4) and data from the December 2023 24/7 RN monthly report.

Response to Correspondence from Senator Ruston to Secretary Comley dated 6 February 2024 regarding Senate Estimates

<u>Question</u>: A breakdown of the current care workforce numbers across Australia, including registered nurses, enrolled nurses, general practitioners, disability care workers and aged care workers

Table 1: Estimated Workforce Supply (Headcount) for Residential Aged Care and Home Care

Residential Aged Care	FY2023-24	FY2024-25	FY2025-26	FY2026-27	FY2027-28	FY2028-29	FY2029-30	FY2030-31	FY2031-32
RNs+NPs	28,382	28,783	29,178	29,572	29,965	30,357	30,750	31,143	31,536
ENs	14,148	14,378	14,603	14,826	15,049	15,272	15,494	15,716	15,939
PCWs	126,078	127,838	129,567	131,287	133,004	134,720	136,437	138,153	139,869
Home Care	FY2023-24	FY2024-25	FY2025-26	FY2026-27	FY2027-28	FY2028-29	FY2029-30	FY2030-31	FY2031-32
RNs+NPs	6,750	6,996	7,243	7,490	7,737	7,983	8,230	8,477	8,724
ENs	1,998	2,069	2,141	2,213	2,285	2,357	2,428	2,500	2,572
PCWs	99,200	102,895	106,590	110,284	113,979	117,673	121,368	125,063	128,757
-	ble are projected developed based of			-			Aged Care provi	der Workforce S	urvey become

available.

3. Figures include all workers in the aged care sector, including agency staff

REQUEST FROM SENATOR RUSTON OF 6 FEBRUARY 2024 – RESIDENTIAL AGED CARE HOME CLOSURES

Questions:

- 1. Is the Department aware of any aged care home closures between 1 June 2023 to 9 February 2024?
 - a. Where have they been located?
 - b. Do you have this broken down by MMM?
- 2. Can the Department provide a list of any providers that have closed over the last 6 months?

Answer:

- There are a variety of reasons for aged care home closures. The most common reasons aged care providers attribute to their decision to close are ageing building stock, financial viability and provider consolidation.
- In the period from 1 June 2023 to 9 February 2024 inclusive, 15 providers opened 16 new residential aged care services and 23¹ services closed.
 - There was an overall increase in the number of operational places, with 1,633 new operational places opened and 1,113 operational places closed in the period.
- The 23 services that closed were in the following locations:
 - o six in New South Wales;
 - eight in Victoria;
 - o four in Western Australia; and
 - o five in Queensland.
- The following residential aged care providers² closed their service in the time period between 1 June 2023 and 9 February 2024 inclusive:

PROVIDER	SERVICE	LOCATION
Anglican Aged Care Services Group	Benetas Lovell House	Victoria
Baptist Union of Queensland	Carinity Summit Cottages	Queensland
Barwon Health	Percy Baxter Lodges	Victoria
Brightwater Care Group Limited	Brightwater Joondalup	Western Australia
Brightwater Care Group Limited	Brightwater Huntingdale	Western Australia
Brightwater Care Group Limited	Brightwater South Lake	Western Australia
Bupa Aged Care Australia Pty Ltd	Bupa Donvale	Victoria
Calvary Aged Care Services Pty Ltd	Japara Central Park	Victoria
Catholic Healthcare	Catholic Healthcare St Mary's Villa	New South Wales

¹ One provider, City of Canning, closed their facility on 1 June 2023 and this was previously reported in SQ23-001647.

² A second provider, Feros Care, NSW relinquished their places on 29 January 2024 with St Andrew Village Ballina Limited, NSW immediately bringing the places online ensuring continuity of care for the residents – this transfer of operations is not counted in service openings or closure data.

Central Coast Community Care Association Limited	Adelene Court Hostel	New South Wales
Churches of Christ in Queensland	Churches of Christ Amaroo Aged Care Service	Queensland
Churches of Christ in Queensland	Churches of Christ Petrie Gardens Aged Care Service	Queensland
Churches of Christ in Queensland	Churches of Christ Woorim Aged Care Service	Queensland
City of Canning ¹	Canning Lodge	Western Australia
Estia Investments Pty Ltd	Estia Health Benalla	Victoria
Estia Investments Pty Ltd	Estia Health Bendigo	Victoria
Lyndoch Living Limited	May Noonan Centre	Victoria
Milford Hall Pty Ltd	Chomley House Hostel	Victoria
Snowy Monaro Regional Council	Snowy River Hostel	New South Wales
Southern Cross Care (NSW & ACT) Limited	Southern Cross Care Moama Residential Aged Care	New South Wales
The Uniting Church in Australia Property Trust (Q.)	Blue Care Bundaberg Millbank Aged Care Facility	Queensland
Wesley Community Services Limited	Wesley Taylor	New South Wales
Wesley Community Services Limited	Wesley Vickery	New South Wales

- The 23 services closed were in the following Monash Modified Model (MMM) regions:
 - twelve in MMM 1;
 - three in MMM 2;
 - one in MMM 3;
 - \circ three in MMM 4; and
 - \circ four in MMM 5.
- A provider, in this context, is defined as an entity which has been approved to provide residential care. Approved providers receive government subsidies for the delivery of care to consumers.
- A service is defined as the business run by an approved provider through which Commonwealth funded aged care services and supports are provided. An approved provider may have multiple services.

Attachment B

Response to Senator Ruston's request of 7 February 2024

2023 COVID-19 Aged Care Support Program as at 8 February 2024:

- 2,035 applications submitted.
- 1,992 applications have been assessed (98%):
 - 1,949 applications deemed eligible for total or partial reimbursement.
 - 22 fully ineligible.
 - o 21 withdrawn.
- 1,705 applications have been sent to DSS for payment totalling \$82 million.
 - 1,082 applications have been paid by DSS totalling \$50 million.
 - 623 applications are with DSS to be paid totalling \$32 million.
- 244 assessments are complete and are being finalised.
- 43 assessments are under review.

As at 8 February 2024, de-identified list of all the outstanding applications (those whereby the payments have yet to be completed) and how much has been claimed by each provider.

De-identified Provider Number	Number of applications	Total funding approved across applications not yet executed			
1	21	\$ 4,266,908.05			
2	58	\$ 3,591,798.63			
3	106	\$ 3,507,541.85			
4	16	\$ 3,457,091.24			
5	51	\$ 2,657,053.05			
6	63	\$ 2,358,691.30			
7	41	\$ 1,823,691.40			
8	13	\$ 1,393,336.40			
9	32	\$ 1,313,785.17			
10	23	\$ 1,227,412.83			
11	6	\$ 1,214,651.36			
12	51	\$ 1,197,324.15			
13	9	\$ 1,135,066.74			
14	19	\$ 1,035,414.86			
15	14	\$ 956,451.15			
16	13	\$ 903,491.57			
17	8	\$ 749,618.62			
18	3	\$ 650,322.00			

De-identified Provider Number	Number of applications	across applie	ing approved cations not yet cuted
19	22	\$	648,124.86
20	9	\$	566,307.78
21	12	\$	534,210.55
22	3	\$	517,629.32
23	5	\$	483,516.28
24	10	\$	468,644.38
25	2	\$	454,644.30
26	3	\$	433,975.98
27	3	\$	339,311.10
28	4	\$	325,421.22
29	6	\$	313,109.99
30	17	\$	290,683.79
31	8	\$	285,271.84
32	3	\$	284,625.98
33	2	\$	275,413.69
34	1	\$	233,351.26
35	29	\$	227,743.69
36	3	\$	205,947.09
37	7	\$	197,241.22
38	3	\$	194,783.61
39	7	\$	193,861.72
40	2	\$	188,931.00
41	4	\$	185,895.92
42	11	\$	182,768.57
43	3	\$	181,700.06
44	1	\$	180,341.00
45	3	\$	173,728.00
46	2	\$	158,613.33
47	2	\$	156,483.12
48	2	\$	150,629.17
49	2	\$	144,877.45
50	1	\$	143,866.70
51	3	\$	142,061.47
52	2	\$	139,626.21
53	4	\$	132,477.69
54	1	\$	131,258.38
55	8	\$	130,883.59
56	4	\$	130,328.76
57	1	\$	129,734.00
58	1	\$	126,520.93
59	1	\$	126,217.01

De-identified Provider Number	Number of applications	across applic	ng approved ations not yet cuted
60	1	\$	112,042.06
61	3	\$	111,720.94
62	4	\$	104,603.35
63	3	\$	103,342.60
64	1	\$	102,750.46
65	1	\$	97,296.90
66	1	\$	95,303.25
67	4	\$	95,086.42
68	7	\$	94,910.55
69	2	\$	94,536.51
70	3	\$	90,811.26
71	1	\$	87,495.53
72	1	\$	87,251.50
73	1	\$	87,197.11
74	3	\$	83,941.23
75	3	\$	79,909.78
76	2	\$	77,784.79
77	1	\$	76,738.13
78	3	\$	74,606.03
79	1	\$	74,392.19
80	1	\$	73,625.51
81	2	\$	73,357.95
82	2	\$	72,072.44
83	1	\$	70,833.48
84	2	\$	70,218.18
85	1	\$	69,554.10
86	1	\$	65,874.90
87	2	\$	64,037.76
88	1	\$	63,243.97
89	1	\$	60,673.76
90	1	\$	59,800.87
91	1	\$	59,453.81
92	1	\$	58,612.91
93	1	\$	57,854.79
94	1	\$	57,468.85
95	1	\$	56,531.58
96	1	\$	54,295.40
97	1	\$	50,862.06
98	3	\$	49,502.67
99	1	\$	48,958.71
100	1	\$	48,784.00

De-identified Provider Number	Number of applications	across applic	ng approved ations not yet cuted
101	1	\$	47,293.76
102	1	\$	46,919.50
103	1	\$	46,826.90
104	1	\$	44,386.00
105	3	\$	44,101.93
106	2	\$	43,868.22
107	1	\$	43,652.93
108	1	\$	41,434.02
109	2	\$	40,709.20
110	3	\$	40,248.17
111	1	\$	39,858.00
112	1	\$	35,967.03
113	5	\$	34,529.68
114	2	\$	34,170.21
115	1	\$	33,829.73
116	1	\$	31,327.00
117	2	\$	30,904.31
118	2	\$	30,759.31
119	1	\$	26,655.82
120	2	\$	25,244.02
121	1	\$	24,514.36
122	2	\$	23,629.11
123	1	\$	23,346.00
124	1	\$	23,122.85
125	1	\$	23,027.45
126	1	\$	22,223.44
127	1	\$	20,980.91
128	2	\$	20,692.32
129	1	\$	19,790.70
130	1	\$	19,713.25
131	1	\$	17,098.94
132	1	\$	15,491.47
133	1	\$	15,271.10
134	1	\$	15,000.00
135	1	\$	15,000.00
136	1	\$	14,997.00
137	1	\$	14,457.55
138	1	\$	14,051.00
139	1	\$	13,352.08
140	1	\$	13,162.46
141	1	\$	12,866.00

De-identified Provider Number	Number of applications	Total funding approved across applications not yet executed			
142	1	\$	12,845.36		
143	1	\$	11,786.13		
144	1	\$	11,188.09		
145	1	\$	11,176.70		
146	1	\$	10,455.91		
147	1	\$	9,680.70		
148	1	\$	9,249.63		
149	2	\$	8,892.03		
150	1	\$	8,602.19		
151	1	\$	8,352.00		
152	1	\$	7,228.72		
153	1	\$	6,372.19		
154	1	\$	6,138.00		
155	1	\$	2,021.26		
156	1	\$	1,090.00		

Attachment A

Aged Care Support Program – Extension Grant as at 8 February 2024

Response to Senator Ruston's request of 7 February 2024

- 11,383 applications have been submitted and assessed (100%):
 - o 11,057 applications deemed eligible for total or partial reimbursement
 - 90 fully ineligible
 - o 236 withdrawn
- 11,007 applications totalling \$986 million have been paid by DSS.
- There are 50 applications with providers pending execution of agreements, totalling \$2 million.
- Between October 2023 and February 2024:
 - 456 (of the initial 11,057 eligible applications) applications have been sent to DSS, payment totalling \$16 million.
 - 1,945 applications have been paid by DSS, totalling \$163 million.

As at 8 February 2024, de-identified list of all the outstanding applications (those whereby the payments have yet to be completed) and how much has been claimed by each provider.

De-identified Provider Number	Number of applications	across ap	otal funding approved oss applications not yet executed			
1	1	\$	588,394.02			
2	1	\$	329,284.98			
3	2	\$	228,857.70			
4	2	\$	152,584.79			
5	1	\$	129,402.66			
6	1	\$	105,501.41			
7	10	\$	92,183.34			
8	1	\$	85,708.99			
9	1	\$	68,201.84			
10	3	\$	66,967.13			
11	1	\$	58,621.43			
12	1	\$	57,841.34			
13	1	\$	56,728.97			
14	1	\$	47,464.21			
15	1	\$	44,050.34			
16	1	\$	34,901.10			
17	1	\$	26,810.55			
18	1	\$	26,478.91			
19	1	\$	25,005.00			
20	1	\$	21,007.82			
21	1	\$	17,398.31			
22	1	\$	8,777.66			
23	4	\$	8,335.06			
24	2	\$	8,087.99			
25	1	\$	5,893.87			
26	1	\$	4,690.35			
27	1	\$	3,957.36			
28	1	\$	3,006.82			
29	1	\$	2,410.46			
30	1	\$	2,001.82			
31	2	\$	1,500.00			
32	1	\$	251.09			

QUESTION ON NOTICE

Supplementary Budget Estimates 2023-2024 Outcome: 0 - Whole of Portfolio

PDR Number: SQ23-002252

Question Subject: Current reviews and completed reviews since 1 July 2022 to 26 October 2023 - Department of Health and Aged Care

Type of Question: Written

Senator: Jane Hume

Question:

26. Please provide a list of the number of reviews that the department/agency is currently conducting.

Please provide:

- a. the name of the review;
- b. the purpose of the review;
- c. the name or names of the reviewer(s);
- d. the remuneration for each of the reviewer(s);
- e. the budgeted cost of the review;
- f. the amount spent to date; and
- g. the date the review is due to be completed.

27. Please provide a list of the number of reviews that the department/agency has completed since 1 July 2022.

Please provide:

- a. the name of the review;
- b. the purpose of the review;
- c. the name or names of the reviewer(s);
- d. the remuneration for each of the reviewer(s);
- e. the budgeted cost of the review;
- f. the amount spent;
- g. the date the review was due to be completed;
- h. the date the review was completed;
- i. the date the review was provided to the Department;
- j. the date the review was provided to the Minister; and
- k. the date the review was provided to the Minister's office.

Answer:

A very wide range of activities can be referred to as reviews, from small internal processes to public, external, Government-initiated processes. Gathering this information on all activities that could be regarded as reviews would require an unreasonable diversion of resources.

	7 1.1.1.2	022	Dava Davammendati					Fabruary 2022 ATA	CL 2022 December Advis				1.6		al Dava	During and Courses in		Abird on Lawrencia and an			
	Adults aged 50 to 64 yes	022 - Updated Winter			ATAGI recommends	2 2022 COV/ID-19 var			GI 2023 Booster Advid		o or confirmed infecti	on (whichovor is the		mber 2023 - Addition is that all adults aged		<u>Primary Course</u> Is defined as any dose of third or lower in sequence adminis individuals, or two doses otherwise.					
	Addits aged 50 to 04 yes	COVID-			ATAGI <u>recommenus</u>				egardless of the numb			on (whichever is the		receive an additional	1 2 75 years siloulu		individuals, or tw	o doses otherwise.			
		vaccin	e.					• • •	ed 65 years and over							This number is an es	timate as a number of	individuals in special c	circumstances will have		
					*Adults age	ed 18-64 years who h	ave medical comorbid	lities that increase the	eir risk of severe COVII	D-19, or disability wit	h significant or comple	ex health needs.	2023 COVID-19 vao	cine dose if 6 months	have passed since	required a difference number of doses to complete a primary course.					
		ed 30 to 49 years <u>can receive</u> a winter booster dose of a COVID-19 vaccine,											their last dose or c	onfirmed infection ar	d that those 65-74		ocompromised individ				
	however th	e benefit for people in	this age group is less	certain.		TAGI advises the following groups should consider a 2023 booster dose if their last COVID-19 vaccine dose or confirmed infection (whichever is the most recent) was 6 months ago or longer, and regardless of the number of prior doses received, based on an individual risk benefit assessment with their immunisation provider.									immunocompromise	who received a Joh	nson and Johnson vacc		ave only required one		
Key changes to ATAGI	The interval second second		CARC Call 2 infantion		months ago or	longer, and regardle					nt with their immunis	ation provider.	should consider an	additional 2023 COV	ID-19 vaccine dose.		de	ose.			
advice between -	The interval recommen	and a winter booster			*Childron an	d adolosconts agod 5			thout risk factors for s that increase their risk		or disability with sign	ificant or complex									
July 2022 and January 2024*	4030	and a writter booster	aose is now 5 months		Cinitaren an	a addreseents aged s	17 years who have h		needs.		or disability with sign	incurre or complex									
					ATAGI advises that	t a booster dose is <u>no</u>	t recommended at thi		nd adolescents aged ur	nder the age of 18 wh	io do not have any risk	factors for severe									
								COVI	ID-19.												
Whole Population	Jul-22	Aug-22	Sep-22	Oct-22	Nov-22	Dec-22	Jan-23	Feb-23	Mar-23	Apr-23	May-23	Jun-23	Jul-23	Aug-23	Sep-23	Oct-23	Nov-23	Dec-23	Jan-24		
Primary Course	22,523,410 (87.7%)	22,544,870 (87.8%)	,	22,569,867 (87.9%)	,	,	,	,	,	,	,	,	,	,	,	,	22,656,236 (88.2%)	,			
Dose 3+	14,247,232 (55.5%)	14,355,439 (55.9%)	14,413,788 (56.1%)			14,530,099 (56.6%)				14,622,606 (56.9%)	14,647,477 (57.0%)	14,666,351 (57.1%)	14,678,618 (57.1%)	14,688,503 (57.2%)		14,700,317 (57.2%)		14,715,403 (57.3%)			
Dose 4+	4,078,518 (15.9%)	4,740,577 (18.5%)	4,932,684 (19.2%)	,		5,456,411 (21.2%)		,	,	5,814,646 (22.6%)	6,031,458 (23.5%)	6,171,493 (24.0%)	6,233,231 (24.3%)	6,267,132 (24.4%)	,			6,385,366 (24.9%)			
Z Dose 5+ Dose 6+	41,647 (0.2%) 1,429 (0.0%)	58,005 (0.2%) 1,738 (0.0%)	66,253 (0.3%) 1,928 (0.0%)	76,054 (0.3%) 2,317 (0.0%)	103,355 (0.4%) 3.284 (0.0%)	122,691 (0.5%) 3.974 (0.0%)	134,425 (0.5%) 4,426 (0.0%)	334,916 (1.3%) 8.144 (0.0%)	925,968 (3.6%) 20,282 (0.1%)	1,591,849 (6.2%)	2,313,277 (9.0%) 53,908 (0.2%)	2,703,246 (10.5%) 66,711 (0.3%)	2,871,549 (11.2%) 73,392 (0.3%)	2,957,203 (11.5%)	3,008,123 (11.7%) 120,142 (0.5%)	3,052,227 (11.9%) 180,983 (0.7%)	3,151,999 (12.3%) 369,288 (1.4%)	3,263,215 (12.7%) 666,339 (2.6%)	3,359,906 (13.1%) 945,220 (3.7%)		
Primary Course	405,109 (89.3%)	405,587 (89.4%)	1,928 (0.0%) 405,899 (89.5%)	2,317 (0.0%) 406,138 (89.5%)	3,284 (0.0%) 406,506 (89.6%)	3,974 (0.0%) 406.885 (89.7%)	4,426 (0.0%) 407,188 (89.8%)	8,144 (0.0%) 407,326 (89.8%)	20,282 (0.1%) 407,489 (89.8%)	35,168 (0.1%) 407,661 (89.9%)	407,926 (89.9%)	408,159 (90.0%)	408.296 (90.0%)	84,675 (0.3%) 408,393 (90.0%)	408,486 (90.1%)	408,567 (90.1%)	408,693 (90.1%)	408,855 (90.1%)	945,220 (3.7%) 408,989 (90.2%)		
Dose 3+	278,798 (61.5%)	280,624 (61.9%)	281,491 (62.1%)	282,081 (62.2%)	282,913 (62.4%)	283,545 (62.5%)	284,032 (62.6%)	284,330 (62.7%)	284,710 (62.8%)	285,106 (62.9%)	285,571 (63.0%)	285,923 (63.0%)	286,133 (63.1%)	286,286 (63.1%)	286,401 (63.1%)	286,511 (63.2%)	286,684 (63.2%)	286,906 (63.3%)	287,069 (63.3%)		
Dose 4+	81,089 (17.9%)	97,950 (21.6%)	103,171 (22.7%)	107,639 (23.7%)	115,239 (25.4%)	119,312 (26.3%)	121,301 (26.7%)	123,172 (27.2%)	126,050 (27.8%)	130,217 (28.7%)	135,772 (29.9%)	139,702 (30.8%)	141,491 (31.2%)	142,499 (31.4%)	143,200 (31.6%)	143,765 (31.7%)	145,071 (32.0%)	146,487 (32.3%)	147,532 (32.5%)		
Dose 5+	1,259 (0.3%)	1,696 (0.4%)	1,932 (0.4%)	2,196 (0.5%)	2,880 (0.6%)	3,358 (0.7%)	3,595 (0.8%)	10,336 (2.3%)	26,534 (5.9%)	43,262 (9.5%)	58,742 (13.0%)	68,027 (15.0%)	71,934 (15.9%)	73,997 (16.3%)	75,504 (16.6%)	76,796 (16.9%)	79,515 (17.5%)	82,224 (18.1%)	84,376 (18.6%)		
Dose 6+	43 (0.0%)	54 (0.0%)	n.p	n.p	90 (0.0%)	102 (0.0%)	116 (0.0%)	272 (0.1%)	703 (0.2%)	1,262 (0.3%)	1,936 (0.4%)	2,317 (0.5%)	2,521 (0.6%)	3,010 (0.7%)	4,858 (1.1%)	7,741 (1.7%)	13,710 (3.0%)	21,626 (4.8%)	28,377 (6.3%)		
Primary Course	7,050,973 (87.1%)	7,058,217 (87.2%)	,,,	1	7,071,088 (87.4%)	7,074,568 (87.4%)	7,078,343 (87.5%)	7,080,439 (87.5%)	7,082,641 (87.5%)	7,084,659 (87.5%)	7,087,267 (87.6%)	7,089,320 (87.6%)	7,090,719 (87.6%)	7,091,891 (87.6%)	7,092,617 (87.6%)	7,093,303 (87.6%)	.,	7,095,528 (87.7%)	.,		
Dose 3+ Dose 4+	4,341,448 (53.6%)	4,381,093 (54.1%)	4,405,221 (54.4%)		4,435,185 (54.8%) 1,695,846 (21.0%)	4,447,406 (54.9%) 1,736,546 (21.5%)	4,457,291 (55.1%)	4,464,399 (55.2%) 1,775,983 (21.9%)	4,472,844 (55.3%)	4,479,665 (55.3%)	4,487,897 (55.4%)	4,493,966 (55.5%)	4,497,754 (55.6%) 1,977.052 (24.4%)	4,500,945 (55.6%) 1.987,588 (24.6%)	4,502,916 (55.6%)	4,504,495 (55.7%) 1,998,828 (24.7%)	4,506,585 (55.7%)	4,509,210 (55.7%)	4,511,516 (55.7%)		
2 Dose 4+ Dose 5+	1,306,507 (16.1%) 15,546 (0.2%)	1,517,273 (18.7%) 21,421 (0.3%)	1,578,079 (19.5%) 24,337 (0.3%)	1,618,433 (20.0%) 27,764 (0.3%)	1,695,846 (21.0%) 37,474 (0.5%)	1,736,546 (21.5%) 44,546 (0.6%)	1,757,651 (21.7%) 49,044 (0.6%)	1,775,983 (21.9%) 111,840 (1.4%)	1,807,012 (22.3%) 299,941 (3.7%)	1,851,989 (22.9%) 508,652 (6.3%)	1,917,173 (23.7%) 729,382 (9.0%)	1,958,589 (24.2%) 845,973 (10.5%)	1,977,052 (24.4%) 897,174 (11.1%)	1,987,588 (24.6%) 925,092 (11.4%)	1,993,900 (24.6%) 942,301 (11.6%)	1,998,828 (24.7%) 956,035 (11.8%)	2,009,267 (24.8%) 984,701 (12.2%)	2,024,230 (25.0%) 1,020,681 (12.6%)	2,036,077 (25.2%) 1,053,424 (13.0%)		
Dose 6+	599 (0.0%)	716 (0.0%)	788 (0.0%)	942 (0.0%)	1.295 (0.0%)	1.610 (0.0%)	1.801 (0.0%)	3.110 (0.0%)	7.663 (0.1%)	12.858 (0.2%)	19.601 (0.2%)	24.186 (0.3%)	26.533 (0.3%)	30,490 (0.4%)	44.089 (0.5%)	64.662 (0.8%)	119.066 (1.5%)	211.437 (2.6%)	300.994 (3.7%)		
Primary Course	4,355,212 (83.5%)	4,359,472 (83.6%)	4,362,314 (83.6%)	4,364,456 (83.6%)	4,366,810 (83.7%)	4,368,504 (83.7%)	4,370,545 (83.8%)	4,371,771 (83.8%)	4,373,006 (83.8%)	4,374,248 (83.8%)	4,375,768 (83.9%)	4,377,089 (83.9%)	4,378,065 (83.9%)	4,379,043 (83.9%)	4,379,556 (83.9%)	4,380,013 (83.9%)	4,380,638 (84.0%)	4,381,306 (84.0%)	4,381,971 (84.0%)		
Dose 3+	2,496,562 (47.8%)	2,517,847 (48.3%)	2,528,583 (48.5%)	2,536,199 (48.6%)	2,546,241 (48.8%)	2,552,994 (48.9%)	2,559,267 (49.1%)	2,563,586 (49.1%)	2,568,370 (49.2%)	2,572,766 (49.3%)	2,578,067 (49.4%)	2,582,198 (49.5%)	2,585,077 (49.5%)	2,587,338 (49.6%)	2,588,760 (49.6%)	2,589,850 (49.6%)	2,591,568 (49.7%)	2,593,207 (49.7%)	2,594,695 (49.7%)		
Dose 4+	805,670 (15.4%)	925,554 (17.7%)	955,626 (18.3%)	976,912 (18.7%)	1,024,127 (19.6%)	1,043,373 (20.0%)	1,053,481 (20.2%)	1,062,159 (20.4%)	1,077,512 (20.7%)	1,101,857 (21.1%)	1,135,985 (21.8%)	1,159,329 (22.2%)	1,170,581 (22.4%)	1,177,262 (22.6%)	1,180,648 (22.6%)	1,183,412 (22.7%)	1,191,215 (22.8%)	1,199,583 (23.0%)	1,206,110 (23.1%)		
Dose 5+	7,505 (0.1%)	10,420 (0.2%)	11,799 (0.2%)	13,292 (0.3%)	18,338 (0.4%)	21,299 (0.4%)	23,143 (0.4%)	58,632 (1.1%)	168,506 (3.2%)	296,134 (5.7%)	426,153 (8.2%)	497,791 (9.5%)	529,439 (10.1%)	546,083 (10.5%)	555,221 (10.6%)	562,848 (10.8%)	584,826 (11.2%)	606,867 (11.6%)	625,654 (12.0%)		
Dose 6+	250 (0.0%)	297 (0.0%)	324 (0.0%)	367 (0.0%)	534 (0.0%)	630 (0.0%) 5.850.732 (89.4%)	696 (0.0%)	1,288 (0.0%)	3,350 (0.1%)	5,915 (0.1%)	8,944 (0.2%)	10,904 (0.2%)	11,995 (0.2%)	13,594 (0.3%)	18,134 (0.3%)	27,152 (0.5%)	64,790 (1.2%)	119,803 (2.3%)	170,686 (3.3%)		
Primary Course Dose 3+	5,834,271 (89.1%) 3,799,018 (58.0%)	5,839,365 (89.2%) 3,823,071 (58.4%)	5,842,515 (89.2%) 3,834,967 (58.6%)	5,844,975 (89.3%) 3,843,942 (58.7%)	5,847,939 (89.3%) 3,854,305 (58.9%)	5,850,732 (89.4%) 3,862,312 (59.0%)	5,853,899 (89.4%) 3,869,300 (59.1%)	5,855,680 (89.4%) 3,874,665 (59.2%)	5,857,515 (89.5%) 3,880,613 (59.3%)	5,859,336 (89.5%) 3,885,760 (59.3%)	5,861,667 (89.5%) 3,891,924 (59.4%)	5,863,567 (89.5%) 3,896,660 (59.5%)	5,864,793 (89.6%) 3,899,815 (59.6%)	5,865,762 (89.6%) 3,902,367 (59.6%)	5,866,504 (89.6%) 3,904,093 (59.6%)	5,867,259 (89.6%) 3,905,653 (59.6%)	5,868,240 (89.6%) 3,907,436 (59.7%)	5,869,490 (89.6%) 3,909,428 (59.7%)	5,870,642 (89.7%) 3,911,460 (59.7%)		
2 Dose 4+	1,001,087 (15.3%)	1,172,065 (17.9%)	1,220,488 (18.6%)	1,256,916 (19.2%)	1,325,890 (20.2%)	1,361,438 (20.8%)	1,378,846 (21.1%)	1,394,729 (21.3%)	1,421,741 (21.7%)	1,462,914 (22.3%)	1,524,982 (23.3%)	1,565,739 (23.9%)	1 583 544 (24 2%)	1,592,470 (24.3%)	1,597,650 (24.4%)	1 602 378 (24 5%)	1,611,459 (24.6%)	1 622 626 (24 8%)	1,631,902 (24.9%)		
Dose 5+	9,868 (0.2%)	13,557 (0.2%)	15,369 (0.2%)	17,854 (0.3%)	24,564 (0.4%)	29,871 (0.5%)	32,981 (0.5%)	82,277 (1.3%)	235,244 (3.6%)	405,223 (6.2%)	592,515 (9.0%)	697,153 (10.6%)	741,718 (11.3%)	762,001 (11.6%)	773,967 (11.8%)	786,296 (12.0%)	807,194 (12.3%)	833,212 (12.7%)	856,585 (13.1%)		
Dose 6+	304 (0.0%)	388 (0.0%)	443 (0.0%)	519 (0.0%)	734 (0.0%)	885 (0.0%)	993 (0.0%)	1,927 (0.0%)	4,806 (0.1%)	8,455 (0.1%)	13,065 (0.2%)	16,443 (0.3%)	18,216 (0.3%)	21,224 (0.3%)	29,422 (0.4%)	46,141 (0.7%)	87,508 (1.3%)	160,666 (2.5%)	231,973 (3.5%)		
Primary Course	1,545,023 (85.7%)	1,546,660 (85.8%)	1,547,764 (85.8%)	1,548,682 (85.9%)	1,549,580 (85.9%)	1,550,300 (86.0%)	1,551,172 (86.0%)	1,551,678 (86.1%)	1,552,284 (86.1%)	1,552,785 (86.1%)	1,553,450 (86.2%)	1,553,950 (86.2%)	1,554,359 (86.2%)	1,554,644 (86.2%)	1,554,900 (86.2%)	1,555,171 (86.2%)	1,555,461 (86.3%)	1,555,736 (86.3%)	1,556,108 (86.3%)		
Dose 3+	1,023,317 (56.8%)	1,032,080 (57.2%)	1,036,397 (57.5%)	1,039,210 (57.6%)	1,042,172 (57.8%)	1,044,093 (57.9%)	1,045,947 (58.0%)	1,047,388 (58.1%)	1,049,119 (58.2%)	1,050,554 (58.3%)	1,052,314 (58.4%)	1,053,614 (58.4%)	1,054,522 (58.5%)	1,055,220 (58.5%)	1,055,713 (58.5%)	1,056,149 (58.6%)	1,056,720 (58.6%)	1,057,200 (58.6%)	1,057,729 (58.7%)		
S Dose 4+ Dose 5+	324,414 (18.0%) 2,750 (0.2%)	371,148 (20.6%) 4.024 (0.2%)	387,927 (21.5%) 4,732 (0.3%)	401,318 (22.3%) 5,537 (0.3%)	420,827 (23.3%) 7.302 (0.4%)	428,307 (23.8%) 8,326 (0.5%)	431,901 (24.0%) 8,890 (0.5%)	435,967 (24.2%) 29.938 (1.7%)	442,998 (24.6%) 87.703 (4.9%)	452,583 (25.1%) 138.948 (7.7%)	465,118 (25.8%) 189,110 (10.5%)	473,367 (26.3%) 217,885 (12.1%)	477,304 (26.5%) 231,514 (12.8%)	479,520 (26.6%) 238.641 (13.2%)	480,940 (26.7%) 243.093 (13.5%)	481,943 (26.7%) 246.550 (13.7%)	484,536 (26.9%) 255,194 (14.2%)	487,022 (27.0%) 262.564 (14.6%)	489,179 (27.1%) 269,259 (14.9%)		
Dose 5+	2,750 (0.2%) 89 (0.0%)	4,024 (0.2%)	4,732 (0.3%) n.p	5,537 (0.3%) 190 (0.0%)	7,302 (0.4%) 312 (0.0%)	8,326 (0.5%) 355 (0.0%)	8,890 (0.5%) 385 (0.0%)	29,938 (1.7%) 713 (0.0%)	87,703 (4.9%) 1,719 (0.1%)	138,948 (7.7%) 2,798 (0.2%)	189,110 (10.5%) 3,919 (0.2%)	217,885 (12.1%) 4,725 (0.3%)	231,514 (12.8%) 5,189 (0.3%)	238,641 (13.2%) 6,201 (0.3%)	243,093 (13.5%) 9,738 (0.5%)	246,550 (13.7%) 14,984 (0.8%)	255,194 (14.2%) 33,760 (1.9%)	262,564 (14.6%) 56,146 (3.1%)	269,259 (14.9%) 78,478 (4.4%)		
Primary Course	192,575 (77.3%)	192,737 (77.3%)	192,859 (77.4%)	190 (0.0%)	193,072 (77.5%)	193,132 (77.5%)	193,192 (77.5%)	193,236 (77.5%)	193,276 (77.6%)	193,322 (77.6%)	193,378 (77.6%)	193,426 (77.6%)	193,452 (77.6%)	193,482 (77.6%)	193,493 (77.6%)	193,526 (77.7%)	193,561 (77.7%)	193,606 (77.7%)	193,637 (77.7%)		
Dose 3+	129,907 (52.1%)	130,835 (52.5%)	131,371 (52.7%)	131,679 (52.8%)	132,016 (53.0%)	132,248 (53.1%)	132,426 (53.1%)	132,549 (53.2%)	132,675 (53.2%)	132,764 (53.3%)	132,903 (53.3%)	133,067 (53.4%)	133,163 (53.4%)	133,245 (53.5%)	133,321 (53.5%)	133,376 (53.5%)	133,455 (53.6%)	133,540 (53.6%)	133,602 (53.6%)		
Dose 4+	17,790 (7.1%)	23,124 (9.3%)	24,851 (10.0%)	25,930 (10.4%)	27,643 (11.1%)	28,899 (11.6%)	29,437 (11.8%)	29,914 (12.0%)	30,484 (12.2%)	31,207 (12.5%)	32,354 (13.0%)	33,210 (13.3%)	33,775 (13.6%)	34,139 (13.7%)	34,373 (13.8%)	34,585 (13.9%)	35,051 (14.1%)	35,562 (14.3%)	35,881 (14.4%)		
Dose 5+	244 (0.1%)	338 (0.1%)	389 (0.2%)	441 (0.2%)	537 (0.2%)	638 (0.3%)	684 (0.3%)	1,206 (0.5%)	3,053 (1.2%)	5,109 (2.1%)	7,964 (3.2%)	9,662 (3.9%)	10,515 (4.2%)	11,016 (4.4%)	11,350 (4.6%)	11,644 (4.7%)	12,353 (5.0%)	13,173 (5.3%)	13,666 (5.5%)		
Dose 6+	12 (0.0%)	n.p	n.p	n.p	n.p	n.p	n.p	39 (0.0%)	75 (0.0%)	110 (0.0%)	173 (0.1%)	234 (0.1%)	270 (0.1%)	307 (0.1%)	387 (0.2%)	484 (0.2%)	1,039 (0.4%)	2,101 (0.8%)	2,934 (1.2%)		
Primary Course	496,957 (87.5%)	497,347 (87.6%)	497,495 (87.6%)	497,635 (87.6%)	497,788 (87.7%)	497,951 (87.7%)	498,105 (87.7%)	498,209 (87.7%)	498,335 (87.7%)	498,472 (87.8%)	498,641 (87.8%)	498,785 (87.8%)	498,887 (87.8%)	498,958 (87.9%)	499,009 (87.9%)	499,058 (87.9%)	499,140 (87.9%)	499,222 (87.9%)	499,292 (87.9%)		
S Dose 3+	323,742 (57.0%) 109,960 (19.4%)	326,165 (57.4%) 128,743 (22.7%)	327,067 (57.6%) 133,641 (23.5%)	327,647 (57.7%) 137,011 (24.1%)	328,284 (57.8%) 143,421 (25.3%)	328,850 (57.9%) 146,596 (25.8%)	329,281 (58.0%) 147,935 (26.0%)	329,651 (58.0%) 149,322 (26.3%)	330,144 (58.1%) 152,053 (26.8%)	330,714 (58.2%) 156,922 (27.6%)	331,553 (58.4%) 164,936 (29.0%)	332,196 (58.5%) 169,828 (29.9%)	332,535 (58.6%) 171,862 (30.3%)	332,781 (58.6%) 172,869 (30.4%)	332,938 (58.6%) 173,432 (30.5%)	333,087 (58.7%) 173,923 (30.6%)	333,322 (58.7%) 174,940 (30.8%)	333,528 (58.7%) 176,047 (31.0%)	333,744 (58.8%) 176,935 (31.2%)		
Dose 4+	1,191 (0.2%)	1,810 (0.3%)	2,098 (0.4%)	2,391 (0.4%)	3,075 (0.5%)	3,632 (0.6%)	3,915 (0.7%)	10,942 (1.9%)	30,121 (5.3%)	51,429 (9.1%)	75,730 (13.3%)	88,661 (15.6%)	93,868 (16.5%)	96,152 (16.9%)	97,505 (17.2%)	98,779 (17.4%)	101,633 (17.9%)	104,507 (18.4%)	106,721 (18.8%)		
Dose 6+	24 (0.0%)	n.p	n.p	n.p	64 (0.0%)	86 (0.0%)	n.p	254 (0.0%)	702 (0.1%)	1,283 (0.2%)	1,944 (0.3%)	2,413 (0.4%)	2,623 (0.5%)	2,985 (0.5%)	4,721 (0.8%)	7,228 (1.3%)	16,127 (2.8%)	26,855 (4.7%)	35,368 (6.2%)		
Primary Course	2,395,864 (87.1%)	2,397,693 (87.2%)	2,398,869 (87.2%)	2,399,872 (87.3%)	2,400,824 (87.3%)	2,401,560 (87.3%)	2,402,367 (87.4%)	2,402,820 (87.4%)	2,403,388 (87.4%)	2,403,957 (87.4%)	2,404,868 (87.5%)	2,405,440 (87.5%)	2,405,753 (87.5%)	2,405,997 (87.5%)	2,406,190 (87.5%)	2,406,379 (87.5%)	2,406,657 (87.5%)	2,407,051 (87.5%)	2,407,377 (87.5%)		
Dose 3+	1,748,418 (63.6%)	1,755,784 (63.8%)	1,759,641 (64.0%)	1,762,667 (64.1%)	1,765,364 (64.2%)	1,767,504 (64.3%)	1,769,207 (64.3%)	1,770,396 (64.4%)	1,771,603 (64.4%)	1,772,705 (64.5%)	1,774,290 (64.5%)	1,775,469 (64.6%)	1,776,185 (64.6%)	1,776,714 (64.6%)	1,777,066 (64.6%)	1,777,387 (64.6%)	1,777,846 (64.7%)	1,778,366 (64.7%)	1,778,817 (64.7%)		
Dose 4+	412,897 (15.0%)	482,050 (17.5%)	504,883 (18.4%)	522,520 (19.0%)	549,161 (20.0%)	564,979 (20.5%)	572,992 (20.8%)	578,578 (21.0%)	585,688 (21.3%)	597,934 (21.7%)	624,853 (22.7%)	640,568 (23.3%)	646,023 (23.5%)	648,864 (23.6%)	650,484 (23.7%)	651,886 (23.7%)	656,388 (23.9%)	661,137 (24.0%)	664,577 (24.2%)		
Dose 5+ Dose 6+	3,027 (0.1%)	4,413 (0.2%)	5,234 (0.2%)	6,192 (0.2%)	8,723 (0.3%)	10,505 (0.4%)	11,612 (0.4%)	28,775 (1.0%)	72,150 (2.6%) 1,183 (0.0%)	138,167 (5.0%) 2,364 (0.1%)	225,691 (8.2%) 4,131 (0.2%)	268,324 (9.8%) 5,252 (0.2%)	284,690 (10.4%) 5,791 (0.2%)	293,089 (10.7%) 6,579 (0.2%)	297,768 (10.8%) 8,430 (0.3%)	301,652 (11.0%) 12,040 (0.4%)	314,457 (11.4%) 32,060 (1.2%)	327,235 (11.9%) 65,505 (2.4%)	337,042 (12.3%)		
	98 (0.0%)	117 (0.0%)	n.p	145 (0.0%)	211 (0.0%)	257 (0.0%)	285 (0.0%)	505 (0.0%)											93,451 (3.4%)		

Data sourced from the Australian Immunisation Register as at 11:59pm 07/02/2024

Specifics Primary Course: Counts the number of people who have commenced a primary course or received at least one dose of any COVID-19 vaccination. Individuals may require multiple doses to complete a primary course depending on vaccine type received and individual circumstances such as severe immunocompromise.

Low Population Suppression: Cells have been suppressed with <10 when the total population in the cell has a value greater than 0 or less than 10. Consequential Suppression: For general population tables, cells have been suppressed with n.p. (n.p. = not provided) where needed to prevent reverse engineering of <10 values, or where relative difference between included values is less than 10. These values are usually larger than 10.

Cumulative Population: Count values included represent total cumulative number of individuals vaccinated up to the end of the month as stated. Back Dated Data: General population records are reported as of encounter date not date of first reporting. This will vary significantly from other published data due to back dated records being recorded at a later date.

Individual Dose Status: Includes all individuals in dose number higher categories. For example, Dose 3+ includes all individuals who have had dose 4 or higher. As a result, state totals by dose number are not additive.

Doses Administered: Includes all doses administered to individuals regardless of dose sequence number.

Caveats

Encounter Month: Is based on the date of physical administration as reported in AIR, not the date of first reporting which may differ from other published figures.

Current Age: Is determined based on an individual's age as of 07 February 2024, individuals may have received their doses while in younger age cohorts.

Medicare Address State: Is based on the patients best known address of 07 February 2024. Individuals may have received their does in different states than they currently reside. End Dated Records: Due to the time series nature of this extract, end dated individuals are included even if they have subsequently died or permanently emigrated from Australia. These individuals are usually removed from point-in-time person level reporting. Incomplete Month: January 2024 data includes data up to 07 February 2024 and is not a complete month.